A cancer diagnosis often brings the prospect of open surgery, prolonged hospital stays, and recovery time. However, certain tumors can be treated using highly focused radiation without surgical incisions or conventional anesthesia.

This is the reality of CyberKnife Robotic Radiosurgery.

While conventional external beam radiation therapy may require multiple sessions over several weeks, and open surgery involves operative risks and recovery, CyberKnife represents a form of stereotactic body radiation therapy (SBRT) that delivers highly precise, high-dose radiation in fewer sessions. For international patients seeking this technology, the Apollo Cancer Centre in Chennai has emerged as a leading provider.

Apollo Chennai is home to South Asia's first CyberKnife S7™ FIM System. At Karetrip, we specialize in connecting international patients to advanced medical technologies. Here is your 2026 guide to understanding how this system works, who it may benefit, and why Apollo Chennai is a preferred destination for treatment.

1. The Technology: South Asia's First CyberKnife S7 FIM

CyberKnife is not a surgical knife; it is a robotic stereotactic radiosurgery system. It uses a compact linear accelerator mounted on a robotic arm to deliver highly focused radiation beams.

The S7 FIM System at Apollo Chennai includes:

• Sub-Millimeter Precision: The robotic arm delivers radiation from multiple angles with high geometric accuracy. While planning aims to minimize exposure to surrounding tissue, some adjacent normal tissue may still receive low-dose radiation depending on tumor location and size.

• Synchrony Motion Tracking: Tumors in areas such as the lungs, liver, or prostate can move with respiration. The Synchrony system uses real-time imaging and motion modeling to track tumor movement and adjust beam delivery dynamically. This improves targeting accuracy but depends on proper patient selection and treatment planning.

• Frameless Immobilization: Unlike older frame-based cranial radiosurgery systems, CyberKnife uses non-invasive immobilization methods such as thermoplastic masks or body molds for positioning, improving patient comfort.

2. Traditional Surgery vs. CyberKnife (The 5-Session Advantage)

For patients traveling internationally, treatment duration is an important consideration.

• Conventional Radiation Therapy: May require daily fractions over 4–8 weeks, depending on cancer type and protocol.

• Traditional Surgery: Involves general anesthesia, operative risks (bleeding, infection), and variable recovery time depending on tumor site.

• CyberKnife Treatment: Typically delivered in 1 to 5 sessions (sometimes more depending on tumor characteristics). Each session may last 30 to 90 minutes. It is usually performed as an outpatient procedure, although suitability depends on tumor type, size, proximity to critical organs, and overall patient health.

Patients generally resume routine non-strenuous activities shortly after treatment, though side effects vary by tumor location and radiation dose.

3. Who is the Ideal Candidate?

CyberKnife is commonly used for selected primary tumors, recurrent tumors, or metastatic lesions where high-precision radiation is beneficial.

Conditions treated at Apollo Chennai may include:

• Brain Tumors: Selected malignant tumors (e.g., certain gliomas, metastases) and benign tumors (e.g., meningiomas, vestibular schwannomas), depending on size and location.

• Prostate Cancer: Often used in selected low- to intermediate-risk localized prostate cancer cases as part of stereotactic body radiation therapy protocols. Suitability depends on staging and urological evaluation.

• Lung and Liver Tumors: Particularly small primary tumors or metastases in patients who are not ideal surgical candidates. Motion tracking helps manage respiratory movement.

• Spinal Tumors: Selected primary or metastatic spinal lesions may be treated with stereotactic radiosurgery, minimizing radiation exposure to the spinal cord.

• Functional Disorders: Certain non-malignant conditions such as trigeminal neuralgia and selected arteriovenous malformations (AVMs) may be treated with stereotactic radiosurgery when clinically indicated.

Not all tumors are suitable for CyberKnife. Large tumors, diffuse disease, or tumors close to highly radiosensitive structures may require alternative approaches.

4. The International Patient Experience with Karetrip

Traveling for cancer treatment can feel overwhelming, but structured coordination improves efficiency.

• Tumor Board Review: Imaging (MRI, PET-CT) and pathology reports are reviewed by radiation oncologists and multidisciplinary tumor boards to determine suitability for stereotactic radiosurgery. Final eligibility is decided by treating specialists.

• Visa Letters: After treatment planning approval, required medical documentation is issued to support visa processing as per hospital and government protocols.

• Outpatient Logistics: Since CyberKnife is typically outpatient-based, patients may stay in nearby serviced apartments rather than hospital wards. Follow-up schedules depend on tumor type and treatment plan.

Conclusion: Precision Treatment with Minimal Invasiveness

CyberKnife offers a non-invasive radiation treatment option for carefully selected patients. It may reduce the number of treatment sessions compared to conventional radiation therapy and avoids surgical incisions. However, it is not universally superior to surgery or standard radiation in all cases. Treatment decisions must be individualized based on tumor biology, stage, patient fitness, and multidisciplinary consultation.

If you are considering CyberKnife, a formal radiation oncology evaluation is essential. Chat with our AI agent, Rua. Securely upload your imaging reports, and coordination can be initiated for specialist review and treatment planning.

Medical Disclaimer

The content provided in this blog is for informational purposes only. CyberKnife is a form of stereotactic radiosurgery and is not suitable for all cancers or tumor sizes (often most appropriate for smaller, well-defined lesions, frequently under approximately 5 cm, though this varies). Side effects may include fatigue, local tissue inflammation, radiation necrosis, or organ-specific complications depending on tumor location. Only a qualified Radiation Oncologist can determine eligibility after full clinical and imaging evaluation. Karetrip facilitates coordination and logistics but does not provide medical advice or clinical decision-making.